课题基金 / 基金详情

Proof-of-Concept and Mechanistic Studies to Repurpose Erectile Dysfunction Drugs for Elderly Females

Proof-of-Concept and Mechanistic Studies to Repurpose Erectile Dysfunction Drugs for Elderly Females
重新利用老年女性勃起功能障碍药物的概念验证和机制研究
批准号:
10714784
负责人:
Se-min Kim
金额:
$42.25万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-05-01 至 2026-02-28

项目摘要

项目成果

Se-min Kim的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 阿尔茨海默病(AD)是一种公共卫生危机,没有有效的治疗方法1。临床前研究使用 一组药物-通常称为“PDE 5A抑制剂”,包括他达拉非、伐地那非和西地那非- 研究表明,抑制磷酸二酯酶5A(PDE 5A)可以改善小鼠的记忆力, 到AD。这就引出了一个问题,这些药物,目前在临床上用于勃起功能障碍, 肺动脉高压,可用于AD患者。这种做法值得进行一次彻底的 研究PDE 5A抑制剂对脑功能的作用机制。然而,复杂性出现了 从结构相关酶PDE 11 A也在各种AD中大量表达的事实来看, 脆弱的大脑区域,如皮质和海马,他达拉非有效抑制PDE 11 A, 尽管与PDE 5A相比具有高7倍的IC 50。因此,我们必须(a)将 抑制PDE 5 A和PDE 11 A对认知丧失的相对作用,和(B)确定PDE 11 A本身是否 一个可以行动的目标为了实现这些目标,我们将首先绘制Pde 5a和Pde 11 a转录本的表达图, 利用qPCR、RNAscope和免疫组织化学在老年小鼠的不同脑区和亚区中进行 和3xTg小鼠(特异性目标1)。然后,我们将立体定向地注射Pde 5a和Pde 11 a的CRISPR构建体 以确定PDE 5A和/或PDE 11 A抑制是否阻止认知功能的恢复。 通过新物体识别和Morris水迷宫测试测量的下降,以及淀粉样蛋白 具体目标2)。根据PA-20-272下行政补编的目标, NOT-AG-22-025,这个为期1年的项目将产生初步数据,用于新的R 01应用,以全面研究 PDE 5A和PDE 11 A在脑功能中的作用。
英文摘要
PROJECT SUMMARY Alzheimer’s disease (AD) is a public health crisis with no effective treatment1. Preclinical studies using a group of drugs—commonly termed "PDE5A inhibitors”, which include tadalafil, vardenafil and sildenafil—have shown that the suppression of the enzyme phosphodiesterase 5A (PDE5A) can improve memory in mice prone to AD. This begs the question whether these drugs, currently in clinical use for erectile dysfunction and pulmonary artery hypertension, can be repurposed for AD patients. Such an approach would merit a thorough investigation into the mechanism of action of PDE5A inhibitors on brain function. Complexities however arise from the fact that the structurally–related enzyme PDE11A is also expressed abundantly in various AD– vulnerable brain regions, such as the cortex and hippocampus, and that tadalafil potently inhibits PDE11A, albeit with a 7–fold higher IC50 compared with PDE5A. It is therefore imperative that we (a) tease apart the relative effects of inhibiting PDE5A and PDE11A on cognitive loss, and (b) determine whether PDE11A is itself an actionable target. Towards these goals, we will first map the expression of Pde5a and Pde11a transcripts using qPCR, RNAscope and immunohistochemistry in various brain regions and sub–regions of aged mice and 3xTg mice (Specific Aim 1). We will then inject CRISPR constructs for Pde5a and Pde11a stereotactically into the hippocampus of 3xTg mice to determine whether PDE5A and/or PDE11A inhibition prevent cognitive decline, measured by the Novel Object Recognition and Morris Water Maze tests, and amyloidogenic protein accumulation (Specific Aim 2). Consistent with the goals of the Administrative Supplement under PA–20–272, NOT–AG–22–025, this 1–year project will yield preliminary data towards a new R01 application to fully study a role for PDE5A and PDE11A in brain function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Proof-of-Concept and Mechanistic Studies to Repurpose Erectile Dysfunction Drugs for Elderly Females
Proof-of-Concept and Mechanistic Studies to Repurpose Erectile Dysfunction Drugs for Elderly Females
Proof-of-Concept and Mechanistic Studies to Repurpose Erectile Dysfunction Drugs for Elderly Females
海外基金